Heron Therapeutics Inc. (NASDAQ:HRTX) saw a downside of -4.62% to close Tuesday at $1.65 after subtracting -$0.08 on the day. The 5-day average trading volume is 2,165,820 shares of the company’s common stock. It has gained $1.7900 in the past week and touched a new high 1 time within the past 5 days. An average of 2,549,220 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,103,276.
HRTX’s 1-month performance is 7.14% or $0.2700 on its low of $1.3600 reached on 08/15/23. The company’s shares have touched a 52-week low of $1.07 and high of $5.14, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, HRTX has lost -34.00% or -$0.8500 and has reached a new high 7 times. However, the current price is down -67.87% from the 52-week high price.
Valuation Metrics
HRTX stock has a beta of 0.95. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.93.
Heron Therapeutics Inc.’s quick ratio for the period ended June 29 was 1.40, with the current ratio over the same period at 1.90.. In terms of profitability, the gross margin trailing 12 months is 45.40%. The trailing 12-month EBITDA margin is -154.51%. The firm’s gross profit as reported stood at $52.8 million against revenue of $107.67 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -34.0% to -$42.06 million, while revenue of -$32.77 million was 22.09% off the previous quarter. Analysts expected HRTX to announce -$0.23 per share in earnings in its latest quarter, but it posted -$0.35, representing a -52.20% surprise. EBITDA for the quarter stood at more than -$41.97 million. HRTX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 240.51 million, with total debt at $156.12 million. Shareholders hold equity totaling $140.76 million.
Let’s look briefly at Heron Therapeutics Inc. (HRTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 52.30% to suggest the stock is trending Neutral, with historical volatility in this time period at 85.52%.
The stock’s 5-day moving average is $1.6560, reflecting a -1.49% or -$0.0250 change from its current price. HRTX is currently trading +9.27% above its 20-day SMA, -2.37% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +33.06% and SMA200 by-55.65%.
Stochastic %K and %D was 62.09% and 58.61% and the average true range (ATR) pointed at 0.1638. The RSI (14) points at 53.91%, while the 14-day stochastic is at 56.86% with the period’s ATR at 0.1573. The stock’s 9-day MACD Oscillator is pointing at 0.0306 and 0.0156 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Heron Therapeutics Inc. (NASDAQ: HRTX), Guggenheim launched coverage with a Buy rating.
